Novel approach for tracheal resection in Morquio a syndrome with end-stage critical airway obstruction: a UK case series
-
Published:2024-07-22
Issue:1
Volume:19
Page:
-
ISSN:1750-1172
-
Container-title:Orphanet Journal of Rare Diseases
-
language:en
-
Short-container-title:Orphanet J Rare Dis
Author:
Kenth JohnnyORCID, Maughan Elizabeth, Butler Colin R, Gabrie Jasleen, Rouhani Maral, Silver Benjamin, Ogunbiyi Olumide K, Wilkinson Stuart, Nandi Reema, Walker Robert, Muthialu Nagarajan, Jones Simon, Hewitt Richard, Bruce Iain A
Abstract
Abstract
Background
Mucopolysaccharidosis (MPS) type IVA is a rare lysosomal storage disorder caused by aberrations of the N-acetyl-galactosamine-6-sulfatase (GALNS) enzyme. MPS IVA is associated with a wide gamut of respiratory and airway disorders that manifest in a continuum of severity. In individuals exhibiting severe phenotypic expression, terminal stages of the disease frequently culminate in life-threatening, critical airway obstruction. These manifestations of end-stage disease are engendered by an insidious progression of multi-level airway pathologies, comprising of tracheomalacia, stenosis, tortuosity and 'buckling'. Historically, the management of end-stage airway disease has predominantly leaned towards palliative modalities. However, contemporary literature has posited that the potential benefits of tracheal resection with aortopexy, performed under cardiopulmonary bypass (CPB), may offer a promising therapeutic option. In this context, we report on outcomes from patients undergoing a novel approach to tracheal resection that is combined with manubrial resection, leading to improved airway calibre, obviating the requisition for CPB.
Results
In this study, seven patients with severe MPS IVA exhibited clinical symptoms and radiological evidence indicative of advanced airway obstruction. All patients had a tracheal resection with a partial upper manubriectomy via transcervical approach, which did not require CPB. The surgical cohort consisted of 5 females and 2 males, the median age was 16 years (range 11-19) and the median height was 105.6cm (range 96.4-113.4). Postoperatively, significant improvements were seen in forced expiratory volume in 1 second (FEV1), with a mean increase of 0.68 litres (95% CI: 0.45-0.91; SD: 0.20). Notably, other spirometry variables also showed meaningful improvements, providing evidence of positive treatment effects. Furthermore, there were no major long-term complications, and the procedure resulted in a significant enhancement in patient-reported domains using PedsQL (version 4.0).
Conclusions
This study represents the largest case series to date, on tracheal resection in patients with severe MPS IVA. Our findings demonstrate the effectiveness of the transcervical approach with partial manubriectomy for improving respiratory function and quality of life for individuals with advanced airway obstruction. Tracheal resection presents a promising treatment modality for severe cases of MPS IVA. Successful outcomes rely on meticulous multidisciplinary assessment, judicious decision-making, and appropriate timing of tracheal surgery. Further research and long-term follow-up studies are warranted to validate the long-term efficacy and safety of this approach.
Funder
NIHR Doctoral Fellowship National MPS Society
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Broomfield A, Kenth J, Bruce IA, Tan HL, Wilkinson S. Respiratory complications of metabolic disease in the paediatric population: a review of presentation, diagnosis and therapeutic options. Paediatr Respir Rev. 2019;32:55. 2. Jones S, Wynn R. Mucopolysaccharidoses: Clinical features and diagnosis - UpToDate. Available from: https://www.uptodate.com/contents/mucopolysaccharidoses-clinical-features-and-diagnosis?search=MPS%20IV&source=search_result&selectedTitle=1~15&usage_type=default&display_rank=1#H10. Cited 2018 Sep 1. 3. Doherty C, Averill LW, Theroux M, Mackenzie WG, Pizarro C, Mason RW, et al. Natural history of Morquio A patient with tracheal obstruction from birth to death. Mol Genet Metab Rep. 2018;14:59–67. 4. Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, et al. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis. 2019;14:137. 5. Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin S-P, Parini R, et al. The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio a subjects. Mol Genet Metab. 2013;109:54–61.
|
|